Provides Phoenix Software to train clinical pharmacology students.
ST. LOUIS, MO – December 13, 2012 – Certara, a leading provider of scientific software and consulting for model-based drug development, announced a new program to support PK/PD modeling and simulation training in China.
The Phoenix platform will be used in a program offered by the Chinese Ministry of Education, to train Chinese students to apply PK/PD modeling and simulation to improve decision making in drug development, by simulating PK/PD outcomes before testing in animals or patients.
The training program will include a number of Phoenix tools, including:
- Phoenix WinNonlin for PK/PD modeling.
- Phoenix NLME for population PK/PD modeling.
- Phoenix Connect to develop workflows that include 3rd party tools.
- IVIVC Toolkit for Phoenix WinNonlin to support in-vitro/in-vivo correlations.
Once a student has completed the training program and successfully completed a certification exam, they will receive a certificate from the Ministry of Education that illustrates their competence in the use of the Phoenix software.
“We are pleased to support the Chinese academic community by helping them develop the next generation of experts that are capable of applying PK/PD modeling to drug development,” said Dr. Daniel Weiner, SVP and GM for Certara. “By using the Phoenix software, the Chinese clinical pharmacology community will join over 4,000 pharma, biotech and academic researchers around the globe today that are applying Phoenix WinNonlin, Phoenix NLME and other tools to support PK/PD modeling and simulation.”
Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp™, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation with scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives.
Diana O’Rourke, 314-951-3310
Director of Marketing